LEUSTATIN

This brand name is authorized in Australia, Brazil, Spain, Japan, Netherlands, New Zealand, South Africa

Active ingredients

The drug LEUSTATIN contains one active pharmaceutical ingredient (API):

1 Cladribine
UNII 47M74X9YT5 - CLADRIBINE

Cladribine is a nucleoside analogue of deoxyadenosine. In resting cells cladribine causes DNA single-strand breaks, rapid nicotinamide adenine dinucleotide consumption, ATP depletion and cell death.

Read about Cladribine

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
L01BB04 Cladribine L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01B Antimetabolites → L01BB Purine analogues
Discover more medicines within L01BB04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: AU Pharmaceutical Benefits Scheme Identifier(s): 4326Q, 7225G
Country: BR Câmara de Regulação do Mercado de Medicamentos Identifier(s): 514501902157315
Country: ES Centro de información online de medicamentos de la AEMPS Identifier(s): 61380
Country: JP 医薬品医療機器総合機構 Identifier(s): 4291408A1021
Country: NL Z-Index G-Standaard Identifier(s): 13927280
Country: NL Z-Index G-Standaard, PRK Identifier(s): 41785
Country: NZ Medicines and Medical Devices Safety Authority Identifier(s): 7163
Country: ZA Health Products Regulatory Authority Identifier(s): 29/26/0404

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.